Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)
Conditions:   Zika;   Chikungunya Interventions:   Biological: ChAdOx1 Zika;   Biological: ChAdOx1 Zika, ChAdOx1 Chik Sponsor:   University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2019 Category: Research Source Type: clinical trials

A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus na ïve Controls.
Condition:   Chikungunya Intervention:   Biological: Chikungunya Sponsors:   PaxVax, Inc.;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2019 Category: Research Source Type: clinical trials

A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines
Condition:   Chikungunya Intervention:   Biological: Chikungunya Sponsors:   PaxVax, Inc.;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2019 Category: Research Source Type: clinical trials

Efficacy of the In2Care ® auto-dissemination device for reducing dengue transmission: study protocol for a parallel, two-armed cluster randomised trial in the Philippines
DiscussionFor decades, it has been commonly accepted that an integrated approach to mosquito control is required. The World Health Organization (WHO) Global Strategic Framework for Integrated Vector Management recommends a range of interventions, in combination, to increase control impact to reduce transmission. This efficacy trial of the first commercial product using the AD approach will be informative in assessing the general utility of AD in reducing not only adult vector densities but, more importantly, reducing the incidence of dengue. The AD technique may complement source reduction and larviciding campaigns by more...
Source: Trials - May 14, 2019 Category: Research Source Type: clinical trials

Phase 2 Study of a Chikungunya Vaccine in Previously Exposed Adults
Condition:   Chikungunya Virus Infection Interventions:   Biological: MV-CHIK;   Other: Placebo Sponsors:   Themis Bioscience GmbH;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials

Chikungunya Vaccine Study in Previously Exposed Adults
Condition:   Chikungunya Virus Infection Interventions:   Biological: MV-CHIK;   Other: Placebo Sponsors:   Themis Bioscience GmbH;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials

Phase 2 Study of a Chikungunya Vaccine in Previously Exposed Adults
Condition:   Chikungunya Virus Infection Interventions:   Biological: MV-CHIK;   Other: Placebo Sponsors:   Themis Bioscience GmbH;   Walter Reed Army Institute of Research (WRAIR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2019 Category: Research Source Type: clinical trials

Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate
Saint-Herblain (France), December 21, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 21, 2018 Category: Pharmaceuticals Source Type: clinical trials

Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
Condition:   Chikungunya Fever Intervention:   Other: Resistance exercise Sponsor:   Universidade Federal de Pernambuco Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2018 Category: Research Source Type: clinical trials